Complement 3 glomerulopathy

This phase II trial tests an experimental drug called QLS7305 in people with several kidney diseases driven by overactivation of the complement system, a part of the immune system. The drug is a small interfering RNA (siRNA) designed to reduce production of complement protein C3,…

This study looks back at the experiences of 35 adults with a rare kidney disease called C3G who received the drug iptacopan through a special early access program in Spain. Researchers will collect information on patient health, lab results, and how the disease responds to treatm…

This early-phase trial tests a new drug called NM8074 in 18 adults with C3 Glomerulopathy (C3G), a rare kidney disease. The drug is given by IV over several weeks to see if it is safe and can reduce protein in the urine, a sign of kidney damage. Researchers will also check how th…

This study tests an investigational drug called LP-005 in 46 adults with complement-mediated kidney disease, a condition where the immune system attacks the kidneys. Participants receive the injection alongside their standard care. The goal is to see if the drug can reduce protei…

This study asks whether levels of uromodulin, a protein in the blood, can indicate the severity of kidney damage in people with lupus nephritis. Researchers will compare uromodulin levels with kidney biopsy results from 90 participants, including those with different classes of l…

This study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is…